Using a domain-focused CRISPR/Cas9 mutagenesis approach, it was shown that the catalytic activity of SETD2 was essential, as mutagenesis of the SETD2 SET domain impaired the proliferation of MLL-AF9-expressing leukemia cells [29]. The gene discussed is KMT2A; the disease is leukemia.